Michael Burkes Brophy Sells 1,442 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,442 shares of Natera stock in a transaction on Monday, January 27th. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54. Following the completion of the sale, the chief financial officer now directly owns 108,032 shares of the company’s stock, valued at approximately $17,487,139.84. The trade was a 1.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Stock Up 0.1 %

Shares of NTRA opened at $168.22 on Thursday. Natera, Inc. has a twelve month low of $64.74 and a twelve month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $166.56 and its 200-day moving average price is $137.43.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. On average, analysts predict that Natera, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the company. Chartwell Investment Partners LLC boosted its stake in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after buying an additional 11,362 shares in the last quarter. Cerity Partners LLC lifted its position in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Natera in the third quarter valued at approximately $385,000. Everence Capital Management Inc. bought a new stake in Natera in the fourth quarter valued at approximately $573,000. Finally, First Turn Management LLC bought a new stake in Natera in the third quarter valued at approximately $19,760,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Morgan Stanley lifted their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. lifted their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, TD Cowen lifted their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.